| Date | Time | Source | Headline | Symbol | Company |
| 07/02/2012 | 11:45AM | Business Wire | Rigrodsky & Long, P.A. Announces Investigation Of Amylin Pharmaceuticals, Inc. Buyout | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 07/02/2012 | 11:40AM | Business Wire | Pomerantz Law Firm Investigates Claims on Behalf of Investors of Amylin Pharmaceuticals Inc. | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 07/02/2012 | 10:50AM | PR Newswire (US) | Amylin Pharmaceuticals, Inc. Shareholder Alert: Bernstein Liebhard LLP Announces Investigation Of Acquisition By Bristol-Myer... | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 07/02/2012 | 8:43AM | Zacks | Bristol-Myers to Buy Amylin - Analyst Blog | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 07/02/2012 | 8:00AM | PR Newswire (US) | Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Amylin Pharmaceuticals, Inc. | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 07/02/2012 | 6:07AM | Edgar (US Regulatory) | Written communication by the subject company relating to a third party tender offer (SC14D9C) | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 07/02/2012 | 6:05AM | Edgar (US Regulatory) | Written communication relating to an issuer or third party (SC TO-C) | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 07/02/2012 | 6:05AM | Edgar (US Regulatory) | Current report filing (8-K) | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 07/02/2012 | 5:16AM | Zacks | Will Good Economic News Continue or Falter? - Analyst Blog | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 07/02/2012 | 5:11AM | Zacks | Ahead of Wall Street - July 2, 2012 - Ahead of Wall Street | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 06/29/2012 | 11:36PM | Dow Jones News | Bristol-Myers to Buy Amylin Pharmaceuticals for $5.3 Billion | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 06/29/2012 | 9:28PM | Business Wire | Bristol-Myers Squibb & AstraZeneca Expand Diabetes Alliance Through Bristol-Myers Squibb’s Acquisition of Amylin Pharmaceut... | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 06/25/2012 | 2:30PM | Business Wire | New Clinical Data Analyses Show Metreleptin Reduced Blood Glucose & Triglyceride Levels in Patients with Rare Forms of Lipody... | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 06/22/2012 | 8:15AM | Zacks | NVO Candidate to Step into Phase III - Analyst Blog | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 06/19/2012 | 11:31AM | Zacks | Update on Amylin's Metreleptin - Analyst Blog | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 06/18/2012 | 6:07AM | Edgar (US Regulatory) | Current report filing (8-K) | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 06/15/2012 | 3:16PM | Edgar (US Regulatory) | Confidential Treatment Order (CT ORDER) | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 06/10/2012 | 8:35PM | Dow Jones News | Novo Nordisk's Victoza More Efficient Than Peers In New Study | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 06/09/2012 | 10:00AM | Business Wire | Once-Weekly BYDUREON™ Provided Greater Glucose Control, Weight Loss & Lower Risk of Hypoglycemia Compared to Once- or Twice... | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 06/09/2012 | 10:00AM | Business Wire | BYDUREON™ Was Associated with Significant and Sustained Glycemic Control at Four Years | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 06/09/2012 | 10:00AM | Business Wire | BYDUREON™ Improved A1C, Fasting Glucose, Pulse Pressure & Weight Regardless of Baseline Body Weight in Patients with Type 2... | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 06/09/2012 | 10:00AM | Business Wire | SYMLIN® Use Helped Patients with Type 2 or Type 1 Diabetes Achieve More Time in Normal Glucose Range | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 06/09/2012 | 8:30AM | Dow Jones News | Sanofi's Lantus Cuts Blood Sugar More Than Merck's Januvia in Diabetes Study | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 06/09/2012 | 8:00AM | Business Wire | BYETTA® Provided Greater Glycemic Durability and Overall Glycemic Control than Amaryl® in Patients with Type 2 Diabetes | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 06/07/2012 | 3:06PM | Edgar (US Regulatory) | Confidential Treatment Order (CT ORDER) | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 06/05/2012 | 9:10AM | Dow Jones News | Amylin is Said To Draw First-Round Bids of Up to $29/Share -Bloomberg | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 06/04/2012 | 4:15PM | Business Wire | Amylin Pharmaceuticals to Present Data on BYDUREON™, BYETTA® and SYMLIN® at the American Diabetes Association 2012 Meeting | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 05/29/2012 | 4:15PM | Business Wire | Amylin Pharmaceuticals to Present at Jefferies 2012 Global Healthcare Conference & Goldman Sachs 33rd Annual Global Healthcar... | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 05/25/2012 | 9:00AM | Marketwired | Today's Economic Outlook - Report Highlights Amylin Pharmaceuticals, Inc. and Wal-Mart Stores, Inc. | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 05/24/2012 | 4:43PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |